The field of RNA therapeutics has expanded incredibly in the past 30 years, and mRNA-based COVID-19 vaccines were just the start.
Clinical trials of an mRNA vaccine have begun, and researchers expect broadly positive outcomes in the fight against the widespread illness.
Unequal access to the COVID-19 vaccine fuelled calls for a patent waiver, but any major change needs to ensure a better outcome for developing economies.
COVID-19 vaccine tourism has swiftly evolved into a thriving global industry as people look to secure a quick vaccination fix.
Dr Harry Al-Wassiti, Research Fellow at the Monash Institute of Pharmaceutical Sciences (MIPS), answers the questions about the jab that's on everyone's mind.
Unprecedented efforts are driving the global push for a safe and effective COVID-19 vaccine. Here's how it's likely to be rolled out in Australia.
We'll struggle to find a vaccine that works perfectly for people who need it most, despite what the headlines say is coming in 2021.
When Monash University announced world-first COVID-19 research in July, the crucial behind-the-scenes work of a group of PhD students went largely unnoticed.
A behind-the-scenes look at the two vaccine candidates being developed by Monash University and the Doherty Institute.
The delivery of a COVID-19 vaccine still needs to overcome some ethical hurdles.
How likely is it that we'll have a relatively quick fix for COVID-19, and what are the hurdles?
Finding a way out of the COVID-19 crisis will firstly require more urgent and coordinated investment in medical innovation.
Critically ill patients from intensive care units are part of a global trial testing a suite of flu and pneumonia drugs in a bid to combat COVID-19.
How prepared are we to give up some personal freedoms, and how do we allocate scarce resources? These are just some of the tough questions we face.
Dummy text
